Financials in USD. Standardized financial statements.
A compact view of how Hisamitsu Pharmaceutical Co., Inc. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $1.09B | $1.02B | $989.35M | $956.96M | $1.08B | $1.08B | $1.29B | $1.30B | $1.33B | $1.35B |
| Revenue Growth? | +6.3% | +3.4% | +3.4% | -11.2% | -0.2% | -16.5% | -0.4% | -2.2% | -1.5% | 0.0% |
| Cost of Revenue? | $446.38M | $424.99M | $438.00M | $414.83M | $449.56M | $427.70M | $489.71M | $495.42M | $499.86M | $499.46M |
| Gross Profit? | $641.32M | $598.01M | $551.35M | $542.13M | $628.40M | $652.57M | $803.57M | $802.80M | $827.43M | $848.12M |
| Gross Margin? | +59.0% | +58.5% | +55.7% | +56.7% | +58.3% | +60.4% | +62.1% | +61.8% | +62.3% | +62.9% |
| Operating Expenses? | $521.77M | $474.10M | $459.42M | $455.62M | $544.66M | $551.89M | $595.08M | $601.10M | $590.95M | $605.19M |
| Operating Income? | $119.55M | $123.91M | $91.94M | $86.51M | $83.74M | $100.68M | $208.49M | $201.69M | $236.48M | $242.93M |
| EBITDA? | $166.59M | $165.45M | $128.04M | $123.44M | $122.49M | $139.16M | $247.48M | $253.67M | $290.38M | $310.97M |
| Income Before Tax | $157.83M | $188.11M | $133.95M | $120.16M | $116.20M | $115.06M | $239.91M | $232.41M | $248.58M | $276.89M |
| Income Tax Expense | $27.38M | $41.87M | $33.19M | $29.73M | $27.74M | $26.08M | $66.45M | $56.98M | $75.10M | $87.20M |
| Net Income? | $127.84M | $142.68M | $97.53M | $87.57M | $86.62M | $87.27M | $171.48M | $173.85M | $171.62M | $188.34M |
| EPS? | $0.45 | $0.48 | $0.32 | $0.28 | $0.27 | $0.27 | $2.09 | $0.52 | $0.51 | $0.56 |
| Diluted EPS? | $0.45 | $0.48 | $0.32 | $0.28 | $0.27 | $0.27 | $2.09 | $0.52 | $0.51 | $0.56 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality